Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia

Abstract: In the phase 3 TOWER study, blinatumomab demonstrated an overall survival benefit over standard-of-care chemotherapy (SOC) in adults with relapsed or refractory (r/r) Philadelphia chromosome–negative (Ph−) B-precursor acute lymphoblastic leukemia (ALL). Nearly all patients in both treatmen...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Anthony S. Stein, Richard A. Larson, Andre C. Schuh, William Stevenson, Ewa Lech-Maranda, Qui Tran, Zachary Zimmerman, William Kormany, Max S. Topp
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2018-07-01
Sarja:	Blood Advances
Linkit:	http://www.sciencedirect.com/science/article/pii/S247395292030940X
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!